GlassScriptPhysician profile
Caroline Howell
NPI 1679537641
$3,515.59
in general payments reported to CMS, 2019-2025
27 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $580 · 2022: $762 · 2023: $479 · 2024: $639 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,073 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.99 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $887.02 | 2021-2025 | |
| Incyte Corporation | $357.50 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $256.71 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $206.39 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $186.05 | 2021-2025 | Ebglyss |
| Regeneron Healthcare Solutions, INC. | $183.72 | 2021-2025 | Dupixent |
| Leo Pharma INC. | $176.30 | 2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $167.40 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $151.33 | 2022 | |
| Galderma Laboratories, L.P. | $131.52 | 2021-2025 | Nemluvio |
| Pfizer INC. | $124.04 | 2021-2025 | |
| Journey Medical Corporation | $79.00 | 2021-2025 | |
| Ucb, INC. | $76.27 | 2021-2025 | Bimzelx |
| Dermavant Sciences, INC. | $73.34 | 2023 | Vtama |
| Mayne Pharma Commercial LLC | $57.89 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.94 | 2021-2024 | Jublia |
| Amgen INC. | $52.52 | 2024-2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $49.82 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $44.87 | 2025 | |
| Verrica Pharmaceuticals INC. | $41.54 | 2024-2025 | Ycanth |
| Almirall LLC | $41.14 | 2025 | Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.59 | 2024 | |
| Sanofi-Aventis U.S. LLC | $18.95 | 2021 | |
| Bard Peripheral Vascular, INC. | $18.09 | 2024 | Venclose Maven Catheter |
| Kyowa Kirin, INC. | $15.30 | 2025 | |
| Hydrofera LLC | $14.92 | 2024 | Hydrofera Blue |
| Biofrontera INC. | $10.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.